AI assistant
IN8BIO, INC. — Director's Dealing 2025
May 8, 2025
35200_dirs_2025-05-07_8bc0c04d-7da1-42f1-967f-f3bcd6300482.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2025-04-27
Reporting Person: Rochlin Kate (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-30 | Common Stock | M | 12295 | $0.1844 | Acquired | 55169 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-27 | Series A Warrants (right to buy) | $0.45 | D | 12295 | Disposed | 2025-10-04 | Common Stock (12295) | Direct |
| 2025-04-27 | Series A Warrants (right to buy) | $0.1844 | A | 12295 | Acquired | 2025-05-02 | Common Stock (12295) | Direct |
| 2025-04-30 | Series A Warrants (right to buy) | $0.1844 | M | 12295 | Disposed | 2025-05-02 | Common Stock (12295) | Direct |
| 2025-04-27 | Series B Warrants (right to buy) | $1.50 | D | 12295 | Disposed | 2028-12-13 | Common Stock (12295) | Direct |
| 2025-04-27 | Series B Warrants (right to buy) | $0.45 | A | 12295 | Acquired | 2028-12-13 | Common Stock (12295) | Direct |
Footnotes
F1: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
F2: Fully vested and exercisable.
F3: The reported securities are included within 12,295 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.
F4: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.